What treatment in 2017 for inoperable pancreatic cancers?
- PMID: 28459988
- DOI: 10.1093/annonc/mdx174
What treatment in 2017 for inoperable pancreatic cancers?
Abstract
Pancreatic adenocarcinoma is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). Though no improvement in patients outcome have been made between 1996 and 2011, since 5 years new treatment options have become available to treat our patients. New standard first line regimens, such as FOLFIRINOX and gemcitabine combined with nab-paclitaxel, have improved overall survivals and second line treatments have been tested and validated. Other first-line treatments have failed, but research remains active and trials are ongoing with promising new anti-cancer agents. These new effective regimens used for MPA have yielded promising results in LAPC patients in open cohorts or phase II trials and a recent trial have failed to demonstrate the added value of classical external radiotherapy in this setting. Here, we review current standards of care in LAPC and MPA, consider the latest challenges and strategic questions, and examine what we may hope for in the future.
Keywords: metastatic disease; pancreatic cancer; treatment.
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.J Cancer Res Clin Oncol. 2019 Feb;145(2):445-455. doi: 10.1007/s00432-018-2789-z. Epub 2018 Nov 14. J Cancer Res Clin Oncol. 2019. PMID: 30430229
-
Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.Hematol Oncol Clin North Am. 2015 Aug;29(4):761-76. doi: 10.1016/j.hoc.2015.04.012. Epub 2015 Jun 9. Hematol Oncol Clin North Am. 2015. PMID: 26226909 Review.
-
Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.Crit Rev Oncol Hematol. 2015 Sep;95(3):318-36. doi: 10.1016/j.critrevonc.2015.03.008. Epub 2015 Apr 15. Crit Rev Oncol Hematol. 2015. PMID: 25921418 Review.
-
Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.Int J Cancer. 2019 Mar 1;144(5):981-990. doi: 10.1002/ijc.31751. Epub 2018 Oct 3. Int J Cancer. 2019. PMID: 30006989 Free PMC article. Clinical Trial.
-
Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?World J Gastroenterol. 2014 Mar 7;20(9):2224-36. doi: 10.3748/wjg.v20.i9.2224. World J Gastroenterol. 2014. PMID: 24605022 Free PMC article. Review.
Cited by
-
The role of pyruvate kinase M2 in anticancer therapeutic treatments.Oncol Lett. 2019 Dec;18(6):5663-5672. doi: 10.3892/ol.2019.10948. Epub 2019 Oct 2. Oncol Lett. 2019. PMID: 31788038 Free PMC article. Review.
-
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.Front Immunol. 2019 Aug 8;10:1832. doi: 10.3389/fimmu.2019.01832. eCollection 2019. Front Immunol. 2019. PMID: 31440238 Free PMC article. Clinical Trial.
-
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.PLoS One. 2018 Jun 1;13(6):e0198038. doi: 10.1371/journal.pone.0198038. eCollection 2018. PLoS One. 2018. PMID: 29856777 Free PMC article.
-
Comprehensive high-throughput image analysis for therapeutic efficacy of architecturally complex heterotypic organoids.Sci Rep. 2017 Nov 30;7(1):16645. doi: 10.1038/s41598-017-16622-9. Sci Rep. 2017. PMID: 29192263 Free PMC article.
-
Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis.Medicine (Baltimore). 2020 Sep 11;99(37):e21687. doi: 10.1097/MD.0000000000021687. Medicine (Baltimore). 2020. PMID: 32925714 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical